- Home
- EICB vs TNGX Comparison
EICB vs TNGX Comparison
Compare EICB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EICB
- TNGX
- Stock Information
- Founded
- EICB N/A
- TNGX 2014
- Country
- EICB
- TNGX United States
- Employees
- EICB N/A
- TNGX N/A
- Industry
- EICB
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EICB
- TNGX Health Care
- Exchange
- EICB Nasdaq
- TNGX Nasdaq
- Market Cap
- EICB N/A
- TNGX 351.2M
- IPO Year
- EICB N/A
- TNGX N/A
- Fundamental
- Price
- EICB $25.04
- TNGX $5.63
- Analyst Decision
- EICB
- TNGX Strong Buy
- Analyst Count
- EICB 0
- TNGX 6
- Target Price
- EICB N/A
- TNGX $12.20
- AVG Volume (30 Days)
- EICB N/A
- TNGX 3.3M
- Earning Date
- EICB N/A
- TNGX 08-06-2025
- Dividend Yield
- EICB N/A
- TNGX N/A
- EPS Growth
- EICB N/A
- TNGX N/A
- EPS
- EICB N/A
- TNGX N/A
- Revenue
- EICB N/A
- TNGX $40,990,000.00
- Revenue This Year
- EICB N/A
- TNGX N/A
- Revenue Next Year
- EICB N/A
- TNGX N/A
- P/E Ratio
- EICB N/A
- TNGX N/A
- Revenue Growth
- EICB N/A
- TNGX 10.09
- 52 Week Low
- EICB N/A
- TNGX $1.03
- 52 Week High
- EICB N/A
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- EICB 61.42
- TNGX 78.55
- Support Level
- EICB $24.90
- TNGX $4.80
- Resistance Level
- EICB $24.98
- TNGX $5.96
- Average True Range (ATR)
- EICB 0.04
- TNGX 0.51
- MACD
- EICB 0.01
- TNGX -0.02
- Stochastic Oscillator
- EICB 100.00
- TNGX 92.95
About EICB Eagle Point Income Company Inc. 7.75% Series B Term Preferred Stock Due 2028
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.